U.S., March 17 -- ClinicalTrials.gov registry received information related to the study (NCT07473960) titled 'IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia' on March 11.
Brief Summary: This is a multi-center, randomized, double-blind, placebo-controlled phase III clinical study evaluating the efficacy and safety of IBI306 monotherapy in Chinese Paricipants with non-familial hypercholesterolemia and mixed hyperlipidemia. Approximately 198 participants were planned to be enrolled in the study. The entire study period includes a screening period of no more than 2 weeks, a run-in period of 4 weeks, a double-blind treatment period of 12 weeks, and a safety follow-up period after the last treatment. Participant...